Skip to main content

Table 2 Incidence of central nervous system (CNS) relapses in patients with breast cancer and types other of solid tumor according to the administered chemotherapy regimen

From: Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status

Patients CNS relapses P value
  n Percentage  
Group A (n = 305) 39 12.8 0.024a
Group B (n = 187) 12 6.5  
Group C (n = 416) 32 7.6 0.196b
Group D (n = 137) 9 6.5  
  1. Group A, patients with breast cancer treated with a taxane-containing regimen; group B, patients with breast cancer treated with a nontaxane-containing regimen; group C, patients with another type of solid tumor type treated with a taxane-containing regimen; and group D, patients with another type of solid tumor treated with a nontaxane-containing regimen. a P value corresponds to the incidence of CNS relapses between groups A and B. b P value corresponds to the incidence of CNS relapses between groups C and D.